Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis

Junshik Hong, Seok Jin Kim, Jae Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung Chul Mun, Young Rok Do, Hun Mo Ryoo, Je Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and Methods: Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. Results: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. Conclusion: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Original languageEnglish
Pages (from-to)173-181
Number of pages9
JournalCancer Research and Treatment
Volume47
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Burkitt Lymphoma
Methotrexate
Doxorubicin
Rituximab
Cytarabine
Vincristine
Korea
Disease-Free Survival
Survival Rate
Retrospective Studies
HIV
Physicians

Keywords

  • Burkitt lymphoma
  • CVAD protocol
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma : Results of a multicenter analysis. / Hong, Junshik; Kim, Seok Jin; Ahn, Jae Sook; Song, Moo Kon; Kim, Yu Ri; Lee, Ho Sup; Yhim, Ho Young; Yoon, Dok Hyun; Kim, Min Kyoung; Oh, Sung Yong; Park, Yong; Mun, Yeung Chul; Do, Young Rok; Ryoo, Hun Mo; Lee, Je Jung; Lee, Jae Hoon; Kim, Won Seog; Suh, Cheolwon.

In: Cancer Research and Treatment, Vol. 47, No. 2, 01.01.2015, p. 173-181.

Research output: Contribution to journalArticle

Hong, J, Kim, SJ, Ahn, JS, Song, MK, Kim, YR, Lee, HS, Yhim, HY, Yoon, DH, Kim, MK, Oh, SY, Park, Y, Mun, YC, Do, YR, Ryoo, HM, Lee, JJ, Lee, JH, Kim, WS & Suh, C 2015, 'Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis', Cancer Research and Treatment, vol. 47, no. 2, pp. 173-181. https://doi.org/10.4143/crt.2014.055
Hong, Junshik ; Kim, Seok Jin ; Ahn, Jae Sook ; Song, Moo Kon ; Kim, Yu Ri ; Lee, Ho Sup ; Yhim, Ho Young ; Yoon, Dok Hyun ; Kim, Min Kyoung ; Oh, Sung Yong ; Park, Yong ; Mun, Yeung Chul ; Do, Young Rok ; Ryoo, Hun Mo ; Lee, Je Jung ; Lee, Jae Hoon ; Kim, Won Seog ; Suh, Cheolwon. / Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma : Results of a multicenter analysis. In: Cancer Research and Treatment. 2015 ; Vol. 47, No. 2. pp. 173-181.
@article{23181941a2de46e2aeca4819ebbce079,
title = "Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis",
abstract = "Purpose: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and Methods: Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. Results: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0{\%}). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9{\%} and 81.4{\%}, respectively. Eleven patients (25.6{\%}) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60{\%} and 65{\%}, which means less than 25{\%} of patients received greater than 80{\%} of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. Conclusion: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.",
keywords = "Burkitt lymphoma, CVAD protocol, Rituximab",
author = "Junshik Hong and Kim, {Seok Jin} and Ahn, {Jae Sook} and Song, {Moo Kon} and Kim, {Yu Ri} and Lee, {Ho Sup} and Yhim, {Ho Young} and Yoon, {Dok Hyun} and Kim, {Min Kyoung} and Oh, {Sung Yong} and Yong Park and Mun, {Yeung Chul} and Do, {Young Rok} and Ryoo, {Hun Mo} and Lee, {Je Jung} and Lee, {Jae Hoon} and Kim, {Won Seog} and Cheolwon Suh",
year = "2015",
month = "1",
day = "1",
doi = "10.4143/crt.2014.055",
language = "English",
volume = "47",
pages = "173--181",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "2",

}

TY - JOUR

T1 - Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma

T2 - Results of a multicenter analysis

AU - Hong, Junshik

AU - Kim, Seok Jin

AU - Ahn, Jae Sook

AU - Song, Moo Kon

AU - Kim, Yu Ri

AU - Lee, Ho Sup

AU - Yhim, Ho Young

AU - Yoon, Dok Hyun

AU - Kim, Min Kyoung

AU - Oh, Sung Yong

AU - Park, Yong

AU - Mun, Yeung Chul

AU - Do, Young Rok

AU - Ryoo, Hun Mo

AU - Lee, Je Jung

AU - Lee, Jae Hoon

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and Methods: Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. Results: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. Conclusion: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

AB - Purpose: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and Methods: Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. Results: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. Conclusion: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

KW - Burkitt lymphoma

KW - CVAD protocol

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84928575545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928575545&partnerID=8YFLogxK

U2 - 10.4143/crt.2014.055

DO - 10.4143/crt.2014.055

M3 - Article

AN - SCOPUS:84928575545

VL - 47

SP - 173

EP - 181

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -